Organon Faces Litigation Over Merger Disclosures as Shareholder Vote Approaches

Details of the New Jersey Lawsuit Against Organon and Board Members

On July 6, 2026, a complaint titled Richard Delman v. Robert Essner, et al., No. MER-C-000047-26, was filed in the Superior Court of New Jersey, County of Mercer Chancery Division. The action names Organon & Co., all current board members, Sun Pharma USA, and Merger Sub as defendants. The complaint alleges that certain disclosures included in Organon's definitive proxy statement filed on June 17, 2026 were materially incomplete and misleading to shareholders considering the proposed merger transaction.

The lawsuit asserts multiple legal claims against the defendants, including violations of the New Jersey Uniform Securities Law under N.J. Stat. § 49:3-71, and common law claims for negligent misrepresentation and concealment, general negligence, and civil conspiracy. Beyond monetary damages, the plaintiff seeks declaratory and injunctive relief intended to prevent the merger from proceeding to a shareholder vote without additional disclosure. On July 13, 2026, the plaintiff filed a motion requesting a preliminary injunction to enjoin the holding of Organon's special meeting and to compel the company to supplement its proxy materials with allegedly omitted information. The court has not yet ruled on this motion as of the report date.

Organon's Response and Voluntary Supplemental Disclosure Strategy

Organon has characterized the complaint allegations as entirely without merit and maintains that no additional disclosure was legally required under applicable securities law. The company explicitly states in the report that it "specifically denies all allegations in the Complaint and any assertion that additional disclosure was or is required." However, Organon determined that voluntarily supplementing the proxy statement would avoid the risk of litigation delaying or otherwise adversely affecting the merger and would minimize the costs, risks, and uncertainties inherent in continued litigation.

Critically, Organon made clear that the voluntary supplemental disclosures provided in this report should not be construed as an admission of legal necessity, materiality, or liability. The company reiterates that nothing in its response constitutes an acknowledgment of wrongdoing. This approach allows Organon to provide shareholders with additional information while preserving its legal position that such disclosures were not mandated by law. As of July 17, 2026, Organon reported being unaware of any other lawsuits challenging the merger or proxy statement, though it acknowledged that additional litigation could be filed in the future.

Supplemental Information on Merger Synergy Estimates Presented to Sun Pharma

In response to the litigation challenge, Organon supplemented its proxy statement with specific detail regarding synergy discussions between the two companies. On January 22, 2026, during preliminary diligence activities and virtual management meetings, Organon presented potential synergies across multiple business segments to Sun Pharma representatives. The company identified preliminary cost synergies across four functional areas: commercial operations, procurement, research and development, and corporate functions. These preliminary synergy estimates were calculated in the aggregate to be approximately $700 million.

This supplemental disclosure directly addresses the merger background and transaction process that shareholders will evaluate when voting on the proposed deal. By providing specific synergy figures and the dates on which management presented this information to the acquirer, the supplement gives shareholders greater visibility into the financial assumptions and strategic rationale that informed Organon's board deliberations. The level of detail regarding business segment opportunities and cost reduction targets across multiple operational functions represents material information for investors assessing the transaction's potential economic benefits.

Board Evaluation of Sun Pharma's Offer and Strategic Alternatives

Organon's supplemental disclosure includes expanded information regarding board deliberations on February 3, 2026, when directors met with company management, Skadden, Arps, Slate, Meagher & Flom LLC (S&C), and Morgan Stanley representatives. During this meeting, Morgan Stanley updated the board on recent communications with Sun Pharma, anticipated transaction timing, and next steps in the process, while also reviewing updated preliminary financial analyses. Board members specifically discussed potential synergies from a transaction with Sun Pharma, including the preliminary synergy estimates that management had previously presented to the acquirer.

The board also engaged in substantive discussion about valuation methodologies, synergy analyses, and a list of select companies for potential future outreach, along with strategic recommendations. Following these deliberations, the board determined its negotiating strategy and authorized leadership to communicate to Sun Pharma that the board was unwilling to pursue a transaction at the initially proposed price of $13.50 per share and remained open to evaluating other alternatives absent a price deemed compelling by directors. This supplemental detail demonstrates the board's active consideration of the transaction price and refusal to accept the initial offer without further negotiation.

Strategic Alternatives Analysis and Execution Risk Considerations

Organon's supplemental disclosure provides substantially more detail regarding strategic alternatives that the board evaluated as part of its fiduciary duties in considering the Sun Pharma merger. During the February 3, 2026 board meeting, a Goldman Sachs representative presented an analysis of sequential transactions that would have involved a merger of equals with an integrated specialty pharmaceutical company, followed by a divestiture of Organon's Established Brands and generics business, acquisitions of innovative pipeline products, and strategic investments in dermatology and women's health categories alongside continued development of the company's pipeline assets.

The board engaged critically with this strategic alternatives presentation, raising questions about the specific companies included in Goldman Sachs's analysis, the geographic scope of proposed transactions, execution risks associated with the multi-step transaction structure, and sensitivity of the analysis to performance assumptions regarding Organon's key products. Following this discussion, directors acknowledged the substantial execution risks embedded in the Goldman Sachs strategic alternatives, including the requirement to identify and secure suitable counterparties for multiple future transactions and to successfully execute a complex series of acquisitions, integrations, and strategic initiatives. This consideration of alternatives and acknowledgment of their associated risks supports the board's ultimate decision to focus on the Sun Pharma proposal.

Organon's Business Segments and the Merger Context

Organon & Co. operates as a diversified pharmaceutical company with business segments spanning Established Brands products, generics, specialty pharmaceutical offerings, and an innovative research and development pipeline. The company's product portfolio includes treatments across women's health, dermatology, and other therapeutic categories. Understanding Organon's business composition is essential context for evaluating both the merger rationale and the strategic alternatives the board considered.

The merger with Sun Pharmaceutical Holdings USA, Inc. represents a significant corporate transformation for Organon, as the company would become a wholly owned subsidiary of Sun Pharma USA following the combination. The financial analyses, synergy estimates, and strategic discussions disclosed in Organon's supplemental materials reflect the board's assessment of how combining with a larger global pharmaceutical manufacturer would position the company relative to pursuing independent strategic initiatives or alternative partnership structures. The disclosure of approximately $700 million in preliminary aggregate cost synergies provides investors with quantified scale on the financial drivers management and the board believed justified the transaction.

Timeline and Process Leading to the Merger Agreement

Organon disclosed that on April 26, 2026, the company entered into an Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc., with Sun Pharma America, Inc. serving as the merger subsidiary. The agreement contemplates that the merger subsidiary will combine with and into Organon, with Organon surviving as a wholly owned subsidiary of Sun Pharma USA. This transaction structure allows Organon's operations to continue as a distinct operating unit within the larger Sun Pharma organization.

The path to the April 26 merger agreement included preliminary diligence by Sun Pharma in January 2026, virtual management meetings between the companies, and a formal expression of interest from Sun Pharma at $13.50 per share, which the Organon board determined was not compelling. The board's subsequent engagement with strategic alternatives and its negotiation of improved terms demonstrate that directors actively managed the process rather than passively accepting the first offer presented. By June 17, 2026, Organon had filed its definitive proxy statement with the Securities and Exchange Commission regarding the special meeting of stockholders scheduled for July 23, 2026, where shareholders would vote on approving the merger.

Special Stockholder Meeting and Voting Procedures

Organon scheduled a special meeting of stockholders for July 23, 2026, at which shareholders would vote on approving the proposed merger with Sun Pharmaceutical Holdings USA, Inc. The definitive proxy statement filed on June 17, 2026 contains the detailed disclosures and information supporting the merger proposal and soliciting shareholder votes. Additional procedural details regarding how shareholders can attend the special meeting are included in the proxy materials themselves.

The July 6, 2026 lawsuit and the plaintiff's July 13, 2026 motion for preliminary injunction created uncertainty regarding whether the special meeting would proceed as scheduled. The court had not ruled on the injunction motion as of July 17, 2026, when Organon filed its supplemental disclosure report. This timing placed substantial pressure on the company to address disclosure concerns proactively before the scheduled vote, as a preliminary injunction delaying the meeting could significantly disrupt the transaction timeline and create extended uncertainty for both Organon shareholders and Sun Pharma.

Financial Analysis and Valuation Considerations in Board Deliberations

Organon's supplemental disclosure references Morgan Stanley providing updated preliminary financial analyses to the board in connection with the merger evaluation and negotiation process. The financial advisor reviewed these analyses with directors during the February 3, 2026 meeting, providing technical support for the board's valuation methodologies discussion and synergy evaluation. While Organon did not disclose the specific financial analyses, projections, or valuation ranges that Morgan Stanley presented, the reference to "updated preliminary financial analyses" indicates that the board received quantitative support for its assessment of transaction value and alternatives.

The board's determination that the initial $13.50 per share offer was not compelling reflects an implicit rejection of the valuation implied by that price, suggesting that Morgan Stanley's analyses supported a higher fair value range or that synergies from the transaction were being valued differently than Sun Pharma's initial proposal contemplated. The eventual merger agreement price was not disclosed in this report, leaving shareholders to review the proxy statement itself for the final agreed-upon consideration and related financial analyses supporting the transaction value.

Ongoing Litigation Risk and Future Disclosure Obligations

Organon acknowledged that as of July 17, 2026, it was not aware of other lawsuits challenging the merger or the definitive proxy statement materials. However, the company noted explicitly that additional lawsuits arising from the merger or proxy disclosures may be filed in the future. This language reflects the reality that securities litigation related to merger transactions frequently develops in stages, with initial complaints followed by additional filings if litigation proceeds or if other shareholders become aware of alleged disclosure deficiencies.

The company's voluntary supplementation strategy appears designed to reduce the attractiveness of future litigation by demonstrating good-faith responsiveness to disclosure concerns, even while denying any legal obligation to provide supplemental information. By proactively supplementing materials before the stockholder vote, Organon may discourage additional plaintiffs from pursuing claims based on the original proxy statement disclosures. Nevertheless, the company has reserved the right to defend vigorously against any claims and continues to maintain that the original disclosures were legally adequate and that the supplement was a voluntary precaution rather than an acknowledgment of deficiency.